FyMed, Inc.

Press Releases

Early Release: FyMed Gets Patent for Novel Immunomodulatory Drug

Pharmaceutical firm FyMed Inc. has received a patent for a novel immunomodulatory drug used in the treatment of autoimmune diseases.
Wilmington, DE

Pharmaceutical firm FyMed Inc. has received a patent for a novel immunomodulatory drug used in the treatment of autoimmune diseases.

FyMed Inc. has been granted a patent for a novel pharmaceutical composition used in the immunomodulatory treatment of autoimmune disorders. These include chronic disabling systemic inflammatory autoimmune disorders, including rheumatoid arthritis. This patent provides for a new formulation that waas developed through precision medicine with significant therapeutic potential for such diseases with high unmet clinical need. "We are pleased to announce this significant milestone which clearly strengthens our intellectual property around our precision medicine drug development program” the Company said.

A formal announcement to soon follow.

About FyMed

FyMed, Inc. is a pharmaceutical company with a growing portfolio of novel and improved pharmaceuticals developed and enhanced through targeted use of next-generation proteomic and genomic technologies in drug discovery and development. Leading innovations in precision medicine has enabled FyMed to effectively balance technological innovation with scientific discovery, creating tools that can productively capitalize on key market deficiencies.

Safe Harbor Statement

To the extent any statements made in this document contain information that is not historical, this news release contains "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words "intends," "plans," "will," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described herein. These risks and uncertainties may include, without limitation, projected expansions, outcomes of our clinical trials, achievement of our business objectives, and the ability to obtain necessary regulatory approvals. FyMed undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.

Contact:

Media Relations, FyMed, Inc.
3422 Old Capitol, Suite 1610
Wilmington, DE 19808
Tel: 302-722-5010
Email: media@fymed.com
http://www.fymed.com/media.html